With analysts around the globe predicting incredible growth in the 3D printing sector in the coming years, Rainbow Coral Corp. announced today that it will extend its investment position in Nano3D Biosciences (n3D), a company on the cutting edge of the 3D bioprinting revolution.
RBCC took an equity interest in n3D in 2012, not long after the companies formed a joint venture to market and develop new technologies for the fast-growing, global biotechnology marketplace. The result of their work has been the BiO Assay, the first commercially available 3D bioprinting system designed for high throughput and high-content drug screening. The automated toxicity assay uses biocompatible magnetic nanoparticles to print cells into 3D structures much faster and more affordably than competing bioprinting technologies.
Because the BiO Assay represents a revolution in pharmaceutical research, offering better and faster results than have previously been possible, RBCC is doubling down on its investment as new and exciting forecasts for the future of the industry come in. In January, for example, Visiongain predicted that the 3D printing market for healthcare will generate more than $4 billion by 2018.
“Nano3D have been excellent partners in our efforts to capitalize on the tremendous growth in demand for these bioprinting innovations,” said RBCC CEO Kimberly Palmer. “Interest is very high in this technology because 3D bioprinting allows for an exceptional degree of personalization and customization, and there’s nothing that requires more personalization than living human tissues.”
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity interest in n3D.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.